ENANTA PHARMACEUTICALS INC — Director's Dealing 2020

Feb 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENANTA PHARMACEUTICALS INC (ENTA)
CIK: 0001177648
Period of Report: 2020-02-26

Reporting Person: CARTER BRUCE L A (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-26	Stock Option (right to buy)	$51.04	A	10000	Acquired	2030-02-26	Common Stock (10000)	Direct

Footnotes

F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 26, 2020), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2021 annual meeting of stockholders.